RSV Immunization
Conditions
Keywords
nirsevimab; nirsevimab immunization rates
Brief summary
The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia. The study will focus on: 1\. Assessing the immunisation rates among eligible infants (born from 1 February 2024 to 15 April 2025) in their first Respiratory Syncytial Virus (RSV)-season in Queensland. Secondary objectives of this study are as follows: 1. To analyse reasons of parents to decide for or against immunisation of their infant with nirsevimab. 1. This objective aims to assess potential influencing factors and evaluate the changes in acceptance across the three cohorts prior and post recommendation. 2. In this regard, demographic factors (e.g. education, income) will be included in the analysis where applicable to gain insights on their potential impact. 2. To assess immunisation rates for further subgroups, e.g. by: a) risk group (defined chronic condition or pre-term birth status), b) regional areas of Queensland. 3. To compare the vaccination coverage rate estimates with data captured via the Australian Immunisation Register.
Interventions
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice
Sponsors
Sanofi
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Be a parent of an infant born between 1 February 2024 and 15 April 2025 * Be at least 18 years of age * Reside in Queensland, Australia * Read and agree to the Participant Information and Consent Form (PICF) before proceeding to the survey * Agree with Adverse Event (AE) reporting requirements before proceeding to the survey
Exclusion criteria
\- Have participated in any studies on infant respiratory diseases in the past 4 months The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of immunised infants among all enrolled infants | March 2026-May 2026 | A descriptive analysis of immunisation status (yes/no) will be performed using summary statistics. |
| Type of immunisation | March 2026-May 2026 | A descriptive analysis of immunisation status (yes/no) will be performed using summary statistics. |
| Location of immunization | March 2026-May 2026 | A descriptive analysis of immunisation status (yes/no) will be performed using summary statistics. |
Countries
Australia
Contacts
CONTACTTrial Transparency email recommended (Toll free for US & Canada)
Outcome results
None listed